| 000 | 01617 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516013959.0 | ||
| 264 | 0 | _c20110815 | |
| 008 | 201108s 0 0 eng d | ||
| 022 | _a1464-3405 | ||
| 024 | 7 |
_a10.1016/j.bmcl.2010.11.027 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeck, Hilary P | |
| 245 | 0 | 0 |
_aImprovement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cMay 2011 |
||
| 300 |
_a2752-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusion Pumps |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-mdm2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xchemical synthesis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xantagonists & inhibitors |
| 700 | 1 | _aDeGraffenreid, Michael | |
| 700 | 1 | _aFox, Brian | |
| 700 | 1 | _aAllen, John G | |
| 700 | 1 | _aRew, Yosup | |
| 700 | 1 | _aSchneider, Stephen | |
| 700 | 1 | _aSaiki, Anne Y | |
| 700 | 1 | _aYu, Dongyin | |
| 700 | 1 | _aOliner, Jonathan D | |
| 700 | 1 | _aSalyers, Kevin | |
| 700 | 1 | _aYe, Qiuping | |
| 700 | 1 | _aOlson, Steven | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 21 _gno. 9 _gp. 2752-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2010.11.027 _zAvailable from publisher's website |
| 999 |
_c20414950 _d20414950 |
||